Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Long Island Bioscience Hub (LIBH) Technology Development RFP
August 23, 2018
Two specific funding programs have been designed to help faculty, physicians, surgeons, medical fellows, and post-docs develop their academic innovations toward commercial goals: Feasibility – up $50k/12 months (director costs) and Proof of Concept- up to $100k/12 months (direct cost) . Full details and application materials can be found here.
Faculty members, physicians, post-doctoral associates, and BEIRs who are considering the submission of an application are strongly encouraged to discuss the proposal with
Anton Xavier (anton.xavier@stonybrook.edu); William Hanes (william.hanes@stonybrook.edu) and/or Emily Kao (Emily.Kao@stonybrook.edu) at the LIBH prior to writing a full proposal..
Deadline for submission is September 19th, 2018. All proposal should be submitted through the online portal. Please note an approval from your Sponsored Programs Office is NOT required prior to the submission but will be required if the project is selected for NIH secondary review. Eligible applicants will be notified if their application is selected to move forward.
The LIBH is supported by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), our four partner institutions, The Research Foundation for SUNY, and Empire State Development.
Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.
The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.
All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.
Kathera Bioscience Inc., a privately-held biotech startup was awarded a SBIR Fast Track grant with a value of up to $3,298,530 from the National Institute of Allergy and Infectious Diseases (NIAID) for its dihydrofolate reductase (DHFR) program. Kathera Bioscience was founded by CFB Advisor and Long Island BIoMentor Initiative Mentor Dr. Stephen Parent.
Kathera is developing novel therapeutics to treat fungal infections, a major cause of human disease with an estimated 11.5 million annual life-threatening infections globally, resulting in more than 1.5 million deaths. The award will fund selection of a lead series in the Phase 1 award and lead optimization in Phase 2. Read more about Kathera and the award here.
[post_title] => Kathera Bioscience Receives SBIR Phase I Fast Track Award To Advance Novel Drugs To Treat Life Threatening Fungal Infections
[post_excerpt] => Kathera Bioscience Inc.,founded by CFB Advisor and Long Island BIoMentor Initiative Mentor Dr. Stephen Parent, was awarded a SBIR Fast Track grant with a value of up to $3,298,530.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => kathera-phase2-2024
[to_ping] =>
[pinged] =>
[post_modified] => 2024-12-10 13:52:57
[post_modified_gmt] => 2024-12-10 18:52:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4380
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4534
[post_author] => 4
[post_date] => 2024-04-08 13:47:00
[post_date_gmt] => 2024-04-08 17:47:00
[post_content] =>
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2499
[post_author] => 4
[post_date] => 2016-11-30 00:57:50
[post_date_gmt] => 2016-11-30 00:57:50
[post_content] => Third round of grants awarded for the development of commercially promising biomedical innovations
The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the third round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $550,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Eighteen months after its establishment, the LIBH has already awarded more than $2M to faculty innovators.
The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property.
A wide range of disciplines are represented in the project awards this cycle including radiology, quantitative biology, biomedical engineering, chemistry, neurosurgery and cancer research. Nine Feasibility awards and one Proof of Concepts award have been funded this cycle. Projects awarded funding in this round include the development of radiotracers for use with PET scans to detect bacterial infections, specifically infective endocarditis (IE); a non-immune-based drug targeting amyloid ß-protein (Aß) for the treatment of mild Alzheimer's disease; DNA nano-carrier platform technology for targeted anti-thrombotic drug delivery in prosthetic heart valve and mechanical circulatory support patients; A medical device utilizing electrical and software engineering in order to detect congenital heart disease in newborn children, and profiling the human immune system through machine learning and bioinformatics. The full list of funded projects can be found on the LIBH webpage.
“The latest announcement of funded project for the LIBH demonstrates the volume of innovation housed within partner institutes that is primed to be moved out of the academic lab and into the commercial sector in order to help patients” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “It is exciting to witness our region’s innovators contemplating their research in ways they hadn’t before, and to see the vibrancy of the bioscience cluster on Long Island growing with each new project proposed.”
“Putting CSHL scientists together with HUB biotech entrepreneurs and industry reviewers is key to the successful translation of early stage ideas resulting from the basic research of Dr. Lingbo Zhang and Mickey Atwal, said Teri Willey, CSHL Vice President Business Development and Technology Transfer. “Zhang’s genetic research on myelodysplastic syndrome will be complimented by experience in medicinal chemistry. Similarly, Atwal’s work on developing therapeutics using physics and math to profile to the immune system will benefit from industry reviewers to guide it toward patient benefit."
“The success of the Long Island Bioscience Hub demonstrates the value of creative partnerships in bringing medical solutions that help address patients’ needs from the research lab to the doctor’s office and the medical clinic. We are proud to be part of the Bioscience Hub’s success,” said Kevin J. Tracey, M.D., President and CEO of the Feinstein Institute.
The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
Download a PDF of the press release here.
[post_title] => Long Island Bioscience Hub Announces Additional Funded Projects
[post_excerpt] => The Long Island Bioscience Hub (LIBH), has announced funding for ten projects totaling $550,000 under the Hub’s technology development and commercialization initiative.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => long-island-bioscience-hub-announces-additional-funded-projects
[to_ping] =>
[pinged] =>
[post_modified] => 2017-01-09 15:08:10
[post_modified_gmt] => 2017-01-09 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2499
[menu_order] => 156
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5031
[post_author] => 3
[post_date] => 2026-08-10 12:17:19
[post_date_gmt] => 2026-08-10 16:17:19
[post_content] =>
Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.
The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.
All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.
